文献速递心力衰竭与心肌病心律失常血脂与心血管预防

CAR-T细胞治疗相关心血管与肺部不良事件:药物警戒研究

Adverse Cardiovascular and Pulmonary Events Associated With Chimeric Antigen Receptor T-Cell Therapy.
PubMed 文献 · J Am Coll Cardiol · 2021-01-01

本回顾性药物警戒研究利用FDA不良事件报告系统,分析靶向CD19的CAR-T产品(阿基仑赛和替沙仑赛)相关心血管与肺部不良事件(CPAEs)。共识别2657例患者报告,其中546例(20.5%)发生CPAEs,68.3%与细胞因子释放综合征重叠。CAR-T与快速性心律失常、心肌病、胸膜疾病和心包疾病报告过度相关,静脉血栓栓塞仅与阿基仑赛相关,CPAEs致死率为30.9%。

要点

  • CAR-T治疗与快速性心律失常、心肌病、胸膜疾病和心包疾病报告过度相关。
  • 静脉血栓栓塞仅与阿基仑赛治疗相关,调整后ROR为1.80。
  • CPAEs致死率达30.9%,需在多学科评估和监测中重视。

核心结论

  • CAR-T治疗与多种心血管和肺部不良事件相关,包括快速性心律失常、心肌病、心包和胸膜疾病及静脉血栓栓塞。

研究设计与样本

  • 回顾性药物警戒研究,利用FDA不良事件报告系统识别阿基仑赛和替沙仑赛相关CPAEs,共2657例患者报告。

主要发现

  • 546例(20.5%)报告CPAEs,其中68.3%(373/546)与细胞因子释放综合征重叠。
  • CAR-T与快速性心律失常(n=74,2.8%,adj.ROR=2.78 [95%CI:2.21-3.51])、心肌病(n=69,2.6%,adj.ROR=3.51 [2.42-5.09])、胸膜疾病(n=46,1.7%,adj.ROR=3.91 [2.92-5.23])和心包疾病(n=11,0.4%,adj.ROR=2.26 [1.25-4.09])报告过度相关,所有IC025>0。
  • 静脉血栓栓塞仅与阿基仑赛相关(n=28,1.6%,adj.ROR=1.80 [1.24-2.62],IC025>0)。
  • 房颤(n=55)是最常见的快速性心律失常,其次为室性心律失常(n=14)。
  • 阿基仑赛较替沙仑赛更常报告快速性心律失常(adj.ROR=1.82 [1.04-3.18])和静脉血栓栓塞(adj.ROR=2.86 [1.18-6.93])。

临床怎么用

  • 对CAR-T治疗接受者应进行多学科评估和监测,关注心血管和肺部不良事件。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Pivotal trials of chimeric antigen receptor T-cell (CAR-T) have identified common toxicities but may have been underpowered to detect cardiovascular and pulmonary adverse events (CPAEs). OBJECTIVES: This study sought to investigate CPAEs associated with commercial CD19-directed CAR-T therapy. METHODS: In this retrospective, pharmacovigilance study, the authors used the Food and Drug Administration adverse event reporting system to identify CPAEs associated with axicabtagene-ciloleucel and tisagenlecleucel. The authors evaluated disproportionate reporting by the reporting odds ratio (ROR) and the lower bound of the information component 95% credibility interval (IC025 >0 is deemed significant). Significant associations were further adjusted to age and sex (adj.ROR). RESULTS: The authors identified CAR-T reports of 2,657 patients, including 546 CPAEs (20.5%). CPAEs overlapped with cytokine release syndrome in 68.3% (373 of 546) of the reports. Compared with the full database, CAR-T was associated with overreporting of tachyarrhythmias (n = 74 [2.8%], adj.ROR = 2.78 [95% CI: 2.21-3.51]), cardiomyopathy (n = 69 [2.6%], adj.ROR = 3.51 [2.42-5.09]), pleural disorders (n = 46 [1.7%], adj.ROR = 3.91 [2.92-5.23]), and pericardial diseases (n = 11 [0.4%], adj.ROR = 2.26 [1.25-4.09], all IC025 >0). Venous thromboembolic events (VTEs) were associated only with axicabtagene-ciloleucel therapy (n = 28 [1.6%], adj.ROR = 1.80 [1.24-2.62], IC025 >0). Atrial fibrillation (n = 55) was the leading tachyarrhythmia, followed by ventricular arrhythmias (n = 14). Tachyarrhythmias and VTEs were reported more often following axicabtagene-ciloleucel than tisagenlecleucel in an age- and sex-adjusted model (adj.ROR = 1.82 [1.04-3.18] and adj.ROR = 2.86 [1.18-6.93], respectively). Finally, the fatality rate of CPAEs was 30.9%. CONCLUSIONS: In this largest post-marketing study to date, the authors identified an association between CAR-T and various CPAEs, including tachyarrhythmias, cardiomyopathy, pericardial and pleural disorders, and VTEs. These findings should be considered in the multidisciplinary assessment for and monitoring of CAR-T therapy recipients.

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Goldman A, Maor E, Bomze D, et al. Adverse Cardiovascular and Pulmonary Events Associated With Chimeric Antigen Receptor T-Cell Therapy. J Am Coll Cardiol. 2021. PMID: 34711339. doi:10.1016/j.jacc.2021.08.044

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。